平衡期对比增强双能CT测定的细胞外容积分数作为IV期胰腺导管腺癌患者的预后因素
本研究纳入66例IV期胰腺导管腺癌患者,于系统化疗前行双能CT检查,计算肿瘤单能CT与双能CT衍生的细胞外容积分数。双能CT衍生细胞外容积分数与单能CT强相关(r=0.965),且仅双能CT衍生细胞外容积分数是多变量分析中无进展生存期(p=0.018)和总生存期(p=0.022)的独立预测因子。
要点
- 双能CT与单能CT衍生的肿瘤细胞外容积分数强相关(r=0.965,p<0.001),Bland-Altman偏倚小(-3.4%)。
- 肿瘤双能CT衍生细胞外容积分数是IV期胰腺导管腺癌化疗患者无进展生存期(p=0.018)和总生存期(p=0.022)的独立预测因子。
- 平衡期对比增强双能CT测定的细胞外容积分数可能作为预测IV期胰腺导管腺癌化疗患者生存的影像生物标志物。
诊断标准与关键数值
- 单能CT与双能CT衍生细胞外容积分数强相关(r=0.965;p<0.001),Bland-Altman图显示小偏倚(-3.4%)。
- 肿瘤单能CT衍生细胞外容积分数升高与无进展生存期获益相关(p=0.002),双能CT衍生细胞外容积分数升高与无进展生存期获益相关(p=0.007)。
- 肿瘤单能CT衍生细胞外容积分数升高与总生存期获益相关(p=0.014),双能CT衍生细胞外容积分数升高与总生存期获益相关(p=0.015)。
- 多变量分析中,仅肿瘤双能CT衍生细胞外容积分数是IV期胰腺导管腺癌化疗患者无进展生存期(p=0.018)和总生存期(p=0.022)的独立预测因子。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the feasibility of equilibrium contrast-enhanced dual-energy CT (DECT), as compared with single-energy CT (SECT) and to calculate extracellular volume (ECV) fraction to predict the survival outcomes of pancreatic ductal adenocarcinoma (PDAC) patients with distant metastases (stage IV) treated with chemotherapy.
METHODS: The study cohort included a total of 66 patients with stage IV PDAC who underwent DECT before systemic chemotherapy between July 2014 and March 2017. Unenhanced and 120-kVp equivalent images during the equilibrium phase were used to calculate tumor SECT-derived ECV fractions, and iodine density images were obtained from equilibrium-phase DECT for DECT-derived ECV fractions. Correlations between SECT- and DECT-derived ECV fractions were identified using the Pearson correlation coefficient and Bland-Altman analysis. The effects of clinical prognostic factors and tumor SECT- and DECT-derived ECV fractions on progression-free survival (PFS) and overall survival (OS) were assessed by univariate and multivariate analyses using Cox proportional hazards models.
RESULTS: The correlation between SECT- and DECT-derived ECV fractions was strong (r = 0.965; p < 0.001). The Bland-Altman plot between SECT- and DECT-derived ECV fractions showed a small bias (- 3.4%). Increasing tumor SECT- and DECT-derived ECV fractions were associated with a positive effect on PFS (SECT, p = 0.002; DECT, p = 0.007) and OS (DECT, p = 0.014; DECT, p = 0.015). Only tumor DECT-derived ECV fraction was an independent predictor of PFS (p = 0.018) and OS (p = 0.022) in patients with stage IV PDAC treated with chemotherapy on multivariate analysis.
CONCLUSIONS: The ECV fraction determined by equilibrium contrast-enhanced DECT can potentially predict the survival of patients with stage IV PDAC treated with chemotherapy.
KEY POINTS: • Extracellular volume fraction of stage IV pancreatic ductal adenocarcinoma determined by dual-energy CT was strongly correlated to that with single-energy CT (r = 0.965, p < 0.001). • Tumor extracellular volume fraction was an independent predictor of progression-free survival (p = 0.018) and overall survival (p = 0.022). • Extracellular volume fraction determined by dual-energy CT could be a useful imaging biomarker to predict the survival of patients with stage IV pancreatic ductal adenocarcinoma treated with chemotherapy.
引用
- Fukukura Y, Kumagae Y, Higashi R, et al. Extracellular volume fraction determined by equilibrium contrast-enhanced dual-energy CT as a prognostic factor in patients with stage IV pancreatic ductal adenocarcinoma. Eur Radiol. 2019. PMID: 31728691. doi:10.1007/s00330-019-06517-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。